HitGen Announces Drug Discovery Collaboration with the Scripps Research Institute and the California Institute for Biomedical Research (Calibr)

HitGen Announces Drug Discovery Collaboration with the Scripps Research Institute and the California Institute for Biomedical Research (Calibr) CHENGDU, China--HitGen Ltd., a privately held biotech company focused on technology for effective and efficient small molecule drug discovery and development, announced today a collaboration with The Scripps Research Institute (TSRI) and its affiliate, the California Institute for Biomedical Research (Calibr). This collaboration is to discover and develop potential new therapies in areas of unmet clinical need, with an initial focus in oncology, regenerative medicine and virology.

HitGen's technology platform, centered around the design, synthesis, and interrogation of multi billion component libraries of DNA encoded small molecules, will be deployed to identify new small molecule leads for therapeutic targets identified by the collaboration. Leaders in basic and translational research at TSRI and Calibr will provide target materials and relevant know how to prosecute drug targets of interest. The parties will contribute in kind to the discovery efforts and anticipate progressing any drug candidates that emerge to clinical proof of concept studies.

We are delighted to partner with HitGen to further the combined TSRI Calibr mission to create new medicines for unmet needs. HitGen's commitment to developing and deploying DEL technology is a great fit for our new model for translational research in the non profit sector, commented Peter Schultz, President and Professor of Chemistry at TSRI, and CEO of Calibr.

We are excited to collaborate with Prof. Schultz and his colleagues at TSRI Calibr as a strategic partner for these discovery efforts, and we acknowledge the fundamental contributions of TSRI Professors Sydney Brenner and Richard Lerner in initiating the field of DNA encoded chemistry technology, said Dr. Jin Li, Chairman & CEO of HitGen Ltd. He added that HitGen continues to grow as a world class drug discovery organization. We are keenly focused on engaging with world leading academic institutions to provide new solutions for unmet medical need.

Contacts HitGen Ltd.

Dr. Jin Li, +86-28-85197385 (Ext. 8001)

Chairman & CEO

or

Dr. Barry Morgan, +1-508-840-9646

Chief Scientific Officer

About The Scripps Research Institute

The Scripps Research Institute (TSRI) is one of the worlds largest independent, not-for-profit organizations focusing on research in the biomedical sciences. TSRI is internationally recognized for its contributions to science and health, including its role in laying the foundation for new treatments for cancer, rheumatoid arthritis, hemophilia, and other diseases. An institution that evolved from the Scripps Metabolic Clinic founded by philanthropist Ellen Browning Scripps in 1924, the institute now employs more than 2,500 people on its campuses in La Jolla, CA, and Jupiter, FL, where its renowned scientists including two Nobel laureates and 20 members of the National Academies of Science, Engineering or Medicine work toward their next discoveries. The institutes graduate program, which awards PhD degrees in biology and chemistry, ranks among the top ten of its kind in the nation. In October 2016, TSRI announced a strategic affiliation with the California Institute for Biomedical Research (Calibr), representing a renewed commitment to the discovery and development of new medicines to address unmet medical needs. For more information, see www.scripps.edu.

# # #

For information:

Office of Communications

Tel: 858-784-2666

Fax: 858-784-8118

press@scripps.edu

LINK:	http://www.scripps.edu/news/press/2017/20170424 HitGen.html...
	See more stories from scripps

Most recent headlines